During the last session, Lucid Diagnostics Inc (NASDAQ:LUCD)’s traded shares were 1.11 million, with the beta value of the company hitting 1.23. At the end of the trading day, the stock’s price was $1.18, reflecting an intraday gain of 5.36% or $0.06. The 52-week high for the LUCD share is $1.80, that puts it down -52.54 from that peak though still a striking 38.98% gain since the share price plummeted to a 52-week low of $0.72. The company’s market capitalization is $127.67M, and the average intraday trading volume over the past 10 days was 1.98 million shares, and the average trade volume was 1.35 million shares over the past three months.
Lucid Diagnostics Inc (LUCD) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. LUCD has a Sell rating from 1 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Lucid Diagnostics Inc (NASDAQ:LUCD) trade information
Lucid Diagnostics Inc (LUCD) registered a 5.36% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.36% in intraday trading to $1.18, hitting a weekly high. The stock’s 5-day price performance is 12.38%, and it has moved by -9.23% in 30 days. Based on these gigs, the overall price performance for the year is 44.13%. The short interest in Lucid Diagnostics Inc (NASDAQ:LUCD) is 1.66 million shares and it means that shorts have 1.38 day(s) to cover.
The consensus price target of analysts on Wall Street is $2, which implies an increase of 41.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $2 respectively. As a result, LUCD is trading at a discount of -69.49% off the target high and -69.49% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -54.43%. While earnings are projected to return 31.90% in 2025, the next five years will return 37.27% per annum.
LUCD Dividends
Lucid Diagnostics Inc is due to release its next quarterly earnings on 2025-May-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lucid Diagnostics Inc (NASDAQ:LUCD)’s Major holders
Lucid Diagnostics Inc insiders own 34.54% of total outstanding shares while institutional holders control 9.78%, with the float percentage being 14.94%. LUMINUS MANAGEMENT LLC is the largest shareholder of the company, while 53.0 institutions own stock in it. As of 2024-06-30, the company held over 0.73 million shares (or 1.6124% of all shares), a total value of $0.6 million in shares.
The next largest institutional holding, with 0.56 million shares, is of VANGUARD GROUP INC’s that is approximately 1.2461% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.46 million.
Also, the Mutual Funds coming in first place with the largest holdings of Lucid Diagnostics Inc (LUCD) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 612.6 shares. This amounts to just over 0.57 percent of the company’s overall shares, with a $0.72 million market value. The same data shows that the other fund manager holds slightly less at 276.27, or about 0.26% of the stock, which is worth about $0.33 million.
